Evidence map›Paper›PMID 37007850›Full record

ArticleSexual medicine2023

STOMp: sexual function trial of overactive bladder medication.

Allison Polland, Jennifer Joy Hamner, Divya Arunachalam, Denicia Shane Dwarica, Ankita Gupta, Jon F Pennycuff, Ann D Tran, Eshetu Tefera, Kate V Meriwether, Robert E Gutman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sexual medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

Allison PollandDepartment of Surgery/Urology, Maimonides Medical Center, Brooklyn, NY 11220, USA.
Jennifer Joy HamnerDepartment of Gynecology, Indiana University, Carmel, IN 46032, USA.
Divya ArunachalamDepartment of Gynecology, Kaiser Permanente Fontana Medical Center, Fontana, CA 92553, USA.
Denicia Shane DwaricaDepartment of Gynecology, University of Missouri, Columbia, MO 65201, USA.
Ankita GuptaDepartment of Gynecology, University of Louisville, Louisville, KY 40215, USA.
Jon F PennycuffDepartment of Gynecology, University of Wisconsin, Madison, WI 53715, USA.
Ann D TranDepartment of Gynecology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Eshetu TeferaDepartment of Biostatistics, Medstar Health Research Institute, Hyattsville, MD 20782, USA.
Kate V MeriwetherDepartment of Gynecology, University of New Mexico, Albuquerque, NM 87131, USA.
Robert E GutmanDepartment of Gynecology, MedStar Georgetown University, Washington, DC 20010, USA.
Icahn School of Medicine at Mount Sinai · USIndiana University · USKaiser Permanente Fontana Medical Center · USMaimonides Medical Center · USMedStar Georgetown University Hospital · USMedStar Health · USUniversity of Louisville · USUniversity of Missouri · USUniversity of New Mexico · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Female sexual function has been shown to improve with overactive bladder (OAB) treatment. Aim: The objective of this study was to evaluate the effects of anticholinergics (ACHs) or a beta-agonist (BAG) on female sexual function. Methods: This was a prospective multicenter cohort study. Sexually active women with OAB completed the Overactive Bladder questionnaire (OAB-q) and Female Sexual Function Index (FSFI) prior to and after 12 weeks of therapy. Sample sizes of 63 per group were calculated to detect a clinically relevant difference in the FSFI. Outcomes: The primary outcome was FSFI change from baseline at 12 weeks. Results: A total of 157 patients were recruited, and 91 completed follow-up (58/108, ACH; 31/49, BAG). There were within-group FSFI differences from pre- to posttreatment: a worsening of arousal in the ACH group ( Clinical Implications: While further research is necessary, this study provides information about the comparative effects of OAB treatments on female sexual function, which may ultimately lead to better patient selection and outcomes. Strengths and Limitations: While there was no difference between the subjects who completed the study and those who did not, the study remained underpowered after the loss to follow-up. The multicenter cohort design allows for generalizability of results. Conclusion: Although this study was underpowered, an improvement in overall sexual function was seen with BAGs, while ACHs were associated with worsening aspects of sexual function.

Indexed as

anticholinergicsbeta-agonistfemale sexual functionoveractive bladder

Identifiers

PMID37007850
PMCPMC10065174
OpenAlexW4315709361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.